MedPath

Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate Resection

Terminated
Conditions
Cancer Prostate
Registration Number
NCT03157856
Lead Sponsor
University Hospital, Grenoble
Brief Summary

In this study, we aim to evaluate the feasibility of anti-PSMA labelling to detect post-operative prostatic tissues by two ex vivo fluorescence techniques. We will evaluate the feasibility and detection of anti-PSMA labelling by:

1. / the FEMTO-ST institute medical device,

2. / the confocal microscope that will be used to measure fluorescence spectra of biological samples.

Detailed Description

For this protocol, 12 patients will be included.

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
8
Inclusion Criteria
  • male patient over 18 years old

  • patient with indication for radical prostatectomy

  • patient with a rectal palpable nodule or targeted MRI positive biopsies or with at least 4 positive biopsies in a hemi-prostate.

    • patient affiliated to French social security system or equivalent
    • patient who have signed a non-opposition form
Exclusion Criteria
  • patient with contraindication to radical prostatectomy
  • patient with remedial prostatectomy
  • patient with normal preoperative MRI or with absence of tumoral area
  • patient with history of hormonal therapy
  • person deprived of freedom by judicial or administrative decision
  • person under legal protection
  • person hospitalized for psychiatric care.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of the fluorescence obtained using the FEMTO-ST device and the confocal microscope of anti-PSMA marked fresh prostate biopsies, for prostatic and non-prostatic tissue, as identified by anatomo-pathology (gold standard).14 months

Fluorescence measurements obtained using the FEMTO-ST medical device and the confocal microscope.

Secondary Outcome Measures
NameTimeMethod
Comparison of the fluorescence obtained using the FEMTO-ST device and the confocal microscope of anti-PSMA marked fresh prostate biopsies, for cancerous and non-cancerous tissue, as identified by anatomo-pathology (gold standard).14 months

Fluorescence measurements obtained using the FEMTO-ST medical device and the confocal microscope.

Trial Locations

Locations (2)

Grenoble Alpes University Hospital - Urology department

🇫🇷

Grenoble, France

Grenoble Alpes University Hospital

🇫🇷

Grenoble, France

Grenoble Alpes University Hospital - Urology department
🇫🇷Grenoble, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.